New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
May 28, 2015
07:55 EDTRRyder signs NGV lease contract with M&B Products
Ryder System has signed a natural gas vehicle lease contract with its new customer in Florida, M&B Products. M&B has signed a full service lease agreement with Ryder for three compressed natural gas heavy duty vehicles. The new CNG trucks will be maintained by Ryder at its Tampa, Fla. service facility located at 4015 N 40th Street.
May 27, 2015
12:36 EDTSNYOn The Fly: Top stock stories at midday
Subscribe for More Information
10:01 EDTBSXOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abbott (ABT) initiated with a Buy at Evercore ISI... Aldeyra (ALDX) initiated with a Buy at Janney Capital... Black Stone Minerals (BSM) initiated with a Neutral at Credit Suisse... Boston Scientific (BSX) initiated with a Buy at Evercore ISI... Cidara Therapeutics (CDTX) initiated with a Buy at BTIG... Coach (COH) initiated with an Underweight at BB&T... Diplomat Pharmacy (DPLO) initiated with an Outperform at Raymond James... EPIRUS (EPRS) initiated with a Buy at BTIG... Enviva (EVA) initiated with a Buy at Citigroup... General Finance Corp (GFN) initiated with an Outperform at Oppenheimer... Hortonworks (HDP) initiated with an Outperform at Oppenheimer... Jarden (JAH) initiated with a Buy at UBS... Kate Spade (KATE) initiated with a Buy at BB&T... Medtronic (MDT) initiated with a Hold at Evercore ISI... MoneyGram (MGI) initiated with a Neutral at Goldman... Opexa Therapeutics (OPXA) initiated with a Buy at Maxim... Paratek Pharmaceuticals (PRTK) initiated with a Buy at BTIG... Progenics (PGNX) initiated with a Buy at BTIG... Rite Aid (RAD) initiated with a Buy at Mizuho... St. Jude Medical (STJ) initiated with a Buy at Evercore ISI... Starwood Waypoint (SWAY) initiated with an Outperform at Wells Fargo... Talen Energy (TLN) initiated with a Hold at Deutsche Bank... Ulta Salon (ULTA) initiated with a Buy at Buckingham... Vipshop (VIPS) initiated with a Buy at Stifel... Virtu Financial (VIRT) initiated with a Neutral at Citigroup... Vista Outdoor (VSTO) initiated with a Buy at Wunderlich... ZELTIQ (ZLTQ) initiated with a Buy at Northcoast... eBay (EBAY) initiated with a Buy at Topeka.
08:01 EDTSNYRetrophin agrees to sell Pediatric PRV to Sanofi
Retrophin (RTRX) announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (SNY). Retrophin received the Pediatric PRV when Cholbam was approved by the U.S. FDA for the treatment of pediatric and adult patients suffering from bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders. Upon closing of the transaction, Retrophin will receive a payment of $150M, followed by two equal installments of $47.5M in 2016 and 2017. The company will receive a total consideration of $245M in cash from Sanofi in exchange for the Pediatric PRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
May 26, 2015
20:47 EDTTERDA Davidson to hold a conference
7th Annual 1:1 Technology Forum is being held in New York on May 27 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link
17:44 EDTBSXBoston Scientific initiated with a Buy at Evercore ISI
Target $20.50.
08:14 EDTSNYBoston Biotech Conferences to hold a conference
Subscribe for More Information
08:01 EDTSNYSanofi's Genzyme to present Aubagio, Lemtrada data at CMSC
Subscribe for More Information
May 25, 2015
15:32 EDTCVSCVS Health shares have 'more gains ahead,' Barron's says
Shares of CVS Health (CVS) remain "reasonably" priced and traders would be wise to stick with the company, Barron's contends in its 'Follow Up' column. Barron's argues that the company's recent purchase of Omnicare (OCR) gives CVS an opportunity to consolidate suppliers and expand its sales to the elderly. Reference Link
14:54 EDTRRyder shares may climb 30% to $125 within 12 months, Barron's says
Subscribe for More Information
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 22, 2015
16:41 EDTCVSStocks end week little changed despite weaker than expected domestic data
Subscribe for More Information
10:52 EDTSNYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
08:47 EDTCVSCVS Health acquisition positive, says SunTrust
Subscribe for More Information
May 21, 2015
19:15 EDTCVSCVS Health should profit from Omnicare acquisition, Barron's says
Subscribe for More Information
16:24 EDTCVSOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:48 EDTSNYRegeneron primary driver remains Praluent, says Piper Jaffray
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
12:49 EDTCVSOn The Fly: Top stock stories at midday
Subscribe for More Information
12:28 EDTCVSGabelli says he likes CVS Health, Walgreens Boots Alliance
Mario Gabelli is speaking on CNBC.
09:28 EDTCVSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Quality Systems (QSII), up 9.5%... Trina Solar (TSL), up 7.1%... Best Buy (BBY), up 7.5%... Kirkland's (KIRK), up 4.3% after reporting quarterly results, guidance, and announcing a $1.50 per share special dividend... Williams-Sonoma (WSM), up 3.8%... salesforce.com (CRM), up 4.8%... Youku Tudou (YOKU), up 1.2%. ALSO HIGHER: CTPartners (CTP), up 30.7% after agreeing to exclusive negotiations to be acquired by DHR International... Omnicare (OCR), up 1.3% after CVS Health (CVS) agrees to acquire the company for $98.00 per share, CVS Health is up 1%... Telenav (TNAV), up 3.3% after being initiated with an Outperform at Northland. DOWN AFTER EARNINGS: NetApp (NTAP), down 11.7%... Rexnord (RXN), down 9.9%... Dollar Tree (DLTR), down 2%. ALSO LOWER: Wave Systems (WAVX), down 22.9% after 7.3M share Spot Secondary priced at 65c... Lumber Liquidators (LL), down 16.5% after CEO resigns... Dicerna Pharmaceuticals (DRNA), down 5.8% after 2.75M share Secondary priced at $17.75.
09:03 EDTCVSOptions expected to be active
Subscribe for More Information
08:54 EDTCVSCVS expects Omnicare deal to have significant synergies, operating efficiencies
Subscribe for More Information
07:57 EDTRRyder expands natural gas vehicle offering into Arkansas
Subscribe for More Information
07:48 EDTCVSCVS Health to hold a conference call
Conference call to discuss definitive agreement to acquire Omnicare will be held on May 21 at 8:30 am. Webcast Link
07:21 EDTCVSOmnicare elevated into CVS Health acquiring for $98 per share
Subscribe for More Information
07:06 EDTCVSCVS Health agree to acquire Omnicare for $98 per share
Subscribe for More Information
07:04 EDTCVSCVS Health agree to acquire Omnicare for $98 per share
Subscribe for More Information
05:15 EDTSNYRegeneron, Sanofi announce positive topline results from sarilumab Phase 3 study
Subscribe for More Information
May 20, 2015
18:19 EDTCVSOmnicare up about 5% from close after talks of being acquired by CVS Health
Subscribe for More Information
18:10 EDTCVSCVS Health in late stage talks to acquire Omnicare, Bloomberg says
CVS Health (CVS) is in advanced talks to buy Omnicare (OCR), Bloomberg reports, citing people with knowledge of the matter. A deal could be reached as soon as this week, the sources added. Reference Link
18:00 EDTCVSCVS Health reportedly in advanced talks to acquire Omnicare, Bloomberg says
Subscribe for More Information
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
07:21 EDTCVSUBS to hold a conference
Subscribe for More Information
05:31 EDTBSXNew study evaluating Boston Scientific Lotus Valve System shows low PVL rates
Subscribe for More Information
May 19, 2015
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
07:17 EDTCVSCVS Health has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO Larry Merlo on May 21 at 11 am.
06:55 EDTSNYGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
13:48 EDTESVEnsco reports departure of chairman Dan Rabun
Subscribe for More Information
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
07:19 EDTSPWElectric Products Group to hold a conference
EPG 2015 is being held in Longboat Key, Florida on May 18-20 with webcasted company presentations to begin on May 18 at 7:30 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
17:39 EDTSPWRelational Investors gives quarterly update on stakes
Subscribe for More Information
10:29 EDTBSX, SNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 14, 2015
10:00 EDTTEROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:41 EDTBSXLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:52 EDTTERTeradyne downgraded to Hold from Buy at Craig-Hallum
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use